| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 03/08/2011 | CA2434272C Novel method and composition for local treatment of meniere's disease, tinnitus and/or hearing loss |
| 03/08/2011 | CA2432126C Complex of modafinil and cyclodextrin |
| 03/08/2011 | CA2426247C Particle formation methods and their products |
| 03/08/2011 | CA2423336C Stabilised fibrate microparticles |
| 03/08/2011 | CA2422531C Topical analgesic compositions containing aliphatic polyamines and methods of using same |
| 03/08/2011 | CA2413334C Stabilized interleukin 2 |
| 03/08/2011 | CA2361251C Formulations comprising antisense nucleotides to connexins |
| 03/08/2011 | CA2311734C Flash-melt oral dosage formulation |
| 03/03/2011 | WO2011026132A2 Methods and compositions for the inhibition of transplant rejection |
| 03/03/2011 | WO2011026125A2 Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen |
| 03/03/2011 | WO2011026122A2 B7-h4 fusion proteins and methods of use thereof |
| 03/03/2011 | WO2011026076A2 Topical formulations comprising a steroid |
| 03/03/2011 | WO2011026041A2 Sdf-1 delivery for treating ischemic tissue |
| 03/03/2011 | WO2011026003A2 A xylitol containing comestible product |
| 03/03/2011 | WO2011025881A1 Film coating composition from solid powder compounds |
| 03/03/2011 | WO2011025158A2 Coacervate having an ionic polymer mixed with the adhesive protein of a mussel or of a species of the variome thereof |
| 03/03/2011 | WO2011025036A1 Particle composition and medicinal composition comprising same |
| 03/03/2011 | WO2011025035A1 Coating composition |
| 03/03/2011 | WO2011024942A1 Matrix metalloprotease-2 (mmp-2) inhibitor |
| 03/03/2011 | WO2011024620A1 Antimycotic pharmaceutical composition |
| 03/03/2011 | WO2011024354A1 Transdermal composition of phosphatidylcholine and method for producing same |
| 03/03/2011 | WO2011024110A2 Glucagon-like peptide-1 receptor (glp-1r) agonists for treating autoimmune disorders |
| 03/03/2011 | WO2011023367A2 Bisphosphonate-prodrugs |
| 03/03/2011 | WO2011023213A1 Modified chemodenervating agents |
| 03/03/2011 | WO2011022861A1 Fulvestrant nanosphere/microsphere and preparative method and use thereof |
| 03/03/2011 | WO2011003858A3 Pharmaceutical compositions and solid forms |
| 03/03/2011 | WO2010148223A3 Anti-vegf antibodies and their uses |
| 03/03/2011 | WO2010141902A3 METHODS FOR IDENTIFICATION OF SITES FOR IgG CONJUGATION |
| 03/03/2011 | WO2010123971A3 Hydrogels for combinatorial delivery of immune-modulating biomolecules |
| 03/03/2011 | WO2010121024A3 Silicone-peroxide compositions for long-term, controlled oxygen release |
| 03/03/2011 | WO2010120489A3 Drug delivery system and methods of use |
| 03/03/2011 | WO2010117957A3 Methods and materials for delivering molecules |
| 03/03/2011 | WO2010117233A3 Stable pharmaceutical composition containing fluvastatin and method for manufacturing the same |
| 03/03/2011 | WO2010117199A3 Coenzyme q10 nanoparticles, preparation method thereof and composition containing said nanoparticles |
| 03/03/2011 | WO2010108077A3 Controlled release particulates containing water-insoluble drug |
| 03/03/2011 | WO2010102997A3 Macromolecules modified by a phosphoramidate and/or phosphonamide group |
| 03/03/2011 | WO2010102991A3 Riluzole liquid emulsions |
| 03/03/2011 | WO2010102923A3 Riluzole aqueous suspensions |
| 03/03/2011 | WO2010091362A3 Topical formulations comprising ion channel modulators |
| 03/03/2011 | WO2010028216A8 Porphyrazine optical and dual optical/mr contrast and therapeutic agents |
| 03/03/2011 | WO2008139264A3 Soft gel formulations |
| 03/03/2011 | WO2008053362A3 Bioresponsive polymers |
| 03/03/2011 | WO2008038155A3 Controlled-release pharmaceutical tablets |
| 03/03/2011 | US20110054392 Implant Material Based On A Polymer System And The Use Thereof |
| 03/03/2011 | US20110054153 Method of purifying apo-2 ligand/trail usin crystallisation the cold |
| 03/03/2011 | US20110054152 Hydroxyalkyl Starch Derivatives |
| 03/03/2011 | US20110054043 Film composition |
| 03/03/2011 | US20110053886 Delayed Self-Gelling Alginate Systems and Uses Thereof |
| 03/03/2011 | US20110053846 The use of gnrh antagonist peptide in the treatement of sex hormone-dependent diseases |
| 03/03/2011 | US20110053845 Localized vaginal delivery without detrimental blood levels |
| 03/03/2011 | US20110053174 Magnetic-nanoparticle conjugates and methods of use |
| 03/03/2011 | US20110052708 Methods and formulations for the delivery of pharmacologically active agents |
| 03/03/2011 | US20110052696 Dendrimers with interior and exterior functionalities comprising of azide or alkyne groups for post-functionalization by the huisgen click cycloaddition |
| 03/03/2011 | US20110052689 Sustained release of guaifenesin |
| 03/03/2011 | US20110052682 Methods for enhancing the release and absorption of water insoluble active agents |
| 03/03/2011 | US20110052659 Implants for administering substances and methods of producing implants |
| 03/03/2011 | US20110052657 Implants for administering substances and methods of producing implants |
| 03/03/2011 | US20110052512 Composition containing a hydroxylated diphenylmethane derivative |
| 03/03/2011 | DE202005021885U1 Hydroxyalkylstärke-Protein-Konjugate, durch reduktive Aminierung hergestellt A hydroxyalkyl starch protein conjugates prepared by reductive amination |
| 03/03/2011 | CA2772610A1 Sdf-1 delivery for treating ischemic tissue |
| 03/03/2011 | CA2772572A1 Bispecific immunocytokine dock-and-lock (dnl) complexes and therapeutic use thereof |
| 03/03/2011 | CA2772301A1 Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
| 03/03/2011 | CA2772204A1 Methods and compositions for the inhibition of transplant rejection |
| 03/03/2011 | CA2772199A1 B7-h4 fusion proteins and methods of use thereof |
| 03/03/2011 | CA2770351A1 Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity |
| 03/03/2011 | CA2770212A1 Film coating composition from solid powder compounds |
| 03/03/2011 | CA2769835A1 Glucagon-like peptide-1 receptor (glp-1r) agonists for treating autoimmune disorders |
| 03/03/2011 | CA2768651A1 Particulate composition and pharmaceutical composition containing the same |
| 03/02/2011 | EP2290091A2 Recombinant measles viruses expressing epitopes of antigens of RNA viruses and use of the recombinant viruses for the preparation of vaccine compositions |
| 03/02/2011 | EP2289970A1 Biocompatible polymers, their process of manufacture and compositions containing them |
| 03/02/2011 | EP2289946A1 A polyglycol modified chitosan oligosaccharide fatty acid graft, preparation method thereof and use of the same |
| 03/02/2011 | EP2289599A2 Compositions comprising neisseria meningitidis antigens from serogroups B and C |
| 03/02/2011 | EP2289567A2 Matrix comprising naturally-occurring crosslinked protein backbone |
| 03/02/2011 | EP2289561A1 Method for preparing molecular complexes |
| 03/02/2011 | EP2289560A2 Polypeptide protracting tags comprising a tetrazole moiety |
| 03/02/2011 | EP2289559A1 Anit-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| 03/02/2011 | EP2289558A1 Bisphosphonate-prodrugs |
| 03/02/2011 | EP2289557A1 Pharmaceutical compositions comprising peranhydrocyclodextrine |
| 03/02/2011 | EP2289551A1 Immunotherapy of autoimmune disorders using antibodies which target B-cells |
| 03/02/2011 | EP2289549A2 Immunoconjugates for treating cancer |
| 03/02/2011 | EP2289548A2 Combined vaccines comprising hepatitis B surface antigen and other antigens |
| 03/02/2011 | EP2289539A1 Zinc-free and low-zinc insulin preparations with improved stability |
| 03/02/2011 | EP2289536A1 Use of bone morphogenetic proteins for healing and repair of connective tissue attachment |
| 03/02/2011 | EP2289517A2 Controlled release oxycodone compositions |
| 03/02/2011 | EP2289506A2 Medicament comprising a C11-C21 alkanoic, alkenoic or alkynoic acid ester and a catechin |
| 03/02/2011 | EP2289495A1 Polysaccharide capsules and methods of preparation |
| 03/02/2011 | EP2289494A1 Polysaccharide capsules and methods of preparation |
| 03/02/2011 | EP2289492A2 Naltrexone hydrochloride compositions |
| 03/02/2011 | EP2289487A1 Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof |
| 03/02/2011 | EP2289486A1 Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof |
| 03/02/2011 | EP2288386A1 Modified linkers |
| 03/02/2011 | EP2288375A1 Pegylated insulin lispro compounds |
| 03/02/2011 | EP2288369A1 Compositions of gnrh related compounds and processes of preparation |
| 03/02/2011 | EP2288368A1 Compositions of peptides and processes of preparation thereof |
| 03/02/2011 | EP2288348A1 Nanoparticles functionalized with sulfated amino alcohols for the inhibition of selectin-mediated cell adhesion |
| 03/02/2011 | EP2288338A1 Stable pharmaceutical formulations |
| 03/02/2011 | EP2288261A2 Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides |
| 03/02/2011 | EP1954710B1 Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides |
| 03/02/2011 | EP1694375B1 Electrically conductive adhesive hydrogels with solubilizer |
| 03/02/2011 | EP1511489B1 New pharmaceutical compositions containing flibanserin polymorph a |